Hopkins Group Uses Ciphergen Chips To Identify Ovarian Cancer Biomarkers | GenomeWeb

Using SELDI technology from Ciphergen, researchers at Johns Hopkins University have identified three protein biomarkers that when combined with the standard CA125 biomarker detected early-stage ovarian cancer in 74 percent of women study patients who had the disease.

The new biomarkers, the latest in a wave of new proteomic biomarker discoveries in this area (See PM 06-11-04), can potentially be developed further as a diagnostic to improve detection of early-stage ovarian cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.